Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
tiistai 9. lokakuuta 2018 päivittänyt: Merck Sharp & Dohme LLC
Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients
This is a randomized, placebo-controlled, 3-period crossover, balanced, single-site, third party-blind study of preladenant (SCH 420814) in participants with Parkinson disease (PD) to be conducted in conformance with Good Clinical Practices.
This trial will investigate the effects of single doses of preladenant and placebo on the dyskinesia and antiparkinsonian actions of a levodopa infusion.
The study will examine 10 mg ("low dose") or 100 mg ("high dose") study drug, given as single, oral administrations in conjunction with intravenous (IV) levodopa infusion and oral carbidopa.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
12
Vaihe
- Vaihe 1
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- Participant must have a diagnosis of idiopathic PD based on history, exam and any relevant laboratory tests
- Participants must have been treated with levodopa for one or more years
- Participants must have motor fluctuations that can be measured as a 10% change in tapping speed between "on" and "off" and concurrent motor Unified PD Rating Scale (UPDRS) must also show a 20% improvement when "on"
- Participants must have dyskinesia when "on" measured as at least 2 in one or more body parts on scale using 0 (absent) to 4 (severe) for four limbs, trunk, neck and face (total 7 body parts and 28 points)
- Participant must be free of any clinically significant disease that would interfere with the study evaluations
- Female participants must be postmenopausal and/or surgically sterilized and have a negative serum pregnancy test at the screening visit and a negative urine or serum pregnancy test upon each admission to the study center
- Premenopausal, unsterilized female participants have to agree to use a medically accepted method of contraception
- Male participants must agree to use a medically accepted method of contraception as or abstain from sexual intercourse during the trial and for 2 months after stopping the medication.
Exclusion Criteria:
- Female participants who are pregnant, intend to become pregnant (within 3 months of ending the study), or are lactating
- Participants with dementia (mini-mental state examination [MMSE] <23), hallucinations, confusion, major psychiatric disorders, and unstable medical conditions
- Participants with any stable surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
- Participants with a positive screen for drugs of abuse
- Participants who are positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)
- Participants who are currently participating in another medical interventional clinical study or have participated in a medical interventional clinical study within 30 days and who have previously received this compound.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: SCH 420814 10 mg→SCH 420814 100 mg→Placebo
Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period.
The levodopa infusion was to be started at Hour 1 and was to run for 2 hours.
The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
|
one 10-mg capsule, orally, at hour 0 of treatment period
single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
Placebo capsule, oral, at hour 0 of treatment period
levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
|
|
Kokeellinen: SCH 420814 100 mg→Placebo→ SCH 420814 10 mg
Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period.
The levodopa infusion was to be started at Hour 1 and was to run for 2 hours.
The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
|
one 10-mg capsule, orally, at hour 0 of treatment period
single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
Placebo capsule, oral, at hour 0 of treatment period
levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
|
|
Kokeellinen: Placebo→SCH 420814 10 mg→SCH 420814 100 mg
Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period.
The levodopa infusion was to be started at Hour 1 and was to run for 2 hours.
The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
|
one 10-mg capsule, orally, at hour 0 of treatment period
single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
Placebo capsule, oral, at hour 0 of treatment period
levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
|
|
Kokeellinen: SCH 420814 10 mg→ Placebo→ SCH 420814 100 mg
Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period.
The levodopa infusion was to be started at Hour 1 and was to run for 2 hours.
The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
|
one 10-mg capsule, orally, at hour 0 of treatment period
single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
Placebo capsule, oral, at hour 0 of treatment period
levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
|
|
Kokeellinen: SCH 420814 100 mg→ SCH 420814 10 mg→Placebo
Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period.
The levodopa infusion was to be started at Hour 1 and was to run for 2 hours.
The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
|
one 10-mg capsule, orally, at hour 0 of treatment period
single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
Placebo capsule, oral, at hour 0 of treatment period
levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
|
|
Kokeellinen: Placebo→ SCH 420814 100 mg→SCH 420814 10 mg
Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period.
The levodopa infusion was to be started at Hour 1 and was to run for 2 hours.
The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
|
one 10-mg capsule, orally, at hour 0 of treatment period
single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
Placebo capsule, oral, at hour 0 of treatment period
levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Mean Peak Dyskinesia Score
Aikaikkuna: Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
Dyskinesia was scored on a scale of 0 (absent), 1 (mild) , 2 (moderate), 3 (severe) and 4 (incapacitating) for seven body parts (face, neck, trunk, each arm and each leg) based on the worse dyskinesia noted during the entire measurement time.
Scores were assessed at Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0.
The dyskinesia score was the sum of the scores for the seven body parts.
The peak dyskinesia score was recorded for each participant regardless of what timepoint the score was achieved.
The total possible score for an individual at each timepoint could range from 0 to 28 with higher scores indicating greater effects of the dyskinesia.
The mean peak dyskinesia score was calculated using the individual peak values.
|
Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Mean Peak Finger Tapping Score
Aikaikkuna: Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
Tapping was measured with two manual counters with keys that were depressed to register a count.
The participant alternately tapped each counter using the index finger of the more affected hand for 60 seconds and was not allowed to use more than one finger to tap.
The participant was instructed to tap as rapidly as possible while being timed for 60 seconds.
The counts were recorded for the two counters at Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0.
The peak tapping score was recorded for each participant regardless of what timepoint the score was achieved.
The mean peak finger tapping score was calculated using the individual peak values.
|
Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
|
Mean Peak Tremor Score
Aikaikkuna: Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
Tremor was scored on a scale of 0 (absent), 1 (mild, 2 (moderate), 3 (severe) and 4 (incapacitating) for seven body parts (face, neck, trunk, each arm and each leg) based on the worse tremor observed during the time spent with participant while taking other study measurements(vital signs, drawing samples, performing the tapping and walking tasks).
Scores were assessed at Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0.
The tremor score was the sum of scores for seven body parts.
The peak tremor score was recorded for each participant regardless of what timepoint the score was achieved.
The total possible score for an individual at each timepoint could range from 0 to 28 with higher scores indicating more effects of the tremors.
The mean peak tremor score was calculated using the individual peak values.
|
Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
|
Mean Peak Walking Speed
Aikaikkuna: Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
Walking speed assessment began with the participant being seated in an armless chair.
Then while being timed, the participant stood up with their arms crossed on their chest and walked 6 meters, turned around, returned to the chair and sat.
Timing was stopped when the participant's buttocks hit the chair and the total time was recorded.
If the participant could not arise in 60 seconds, 60 seconds was entered in this line of the report form and the participant was tested again but allowed to push off to get out of the chair.
Sixty seconds was the maximum time allowed to complete the walking assessment, thus 60 seconds was recorded as the time if they could not complete the task within this time limit.
Walking speed was assessed at Hours 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7.0 and 8.
The peak walking speed was recorded for each participant regardless of what timepoint the score was achieved.
The mean peak walking speed was calculated using the individual peak values.
|
Hours 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0 and 8.0 of each treatment period
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Tiistai 21. huhtikuuta 2009
Ensisijainen valmistuminen (Todellinen)
Perjantai 30. huhtikuuta 2010
Opintojen valmistuminen (Todellinen)
Perjantai 14. toukokuuta 2010
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Perjantai 13. helmikuuta 2009
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Perjantai 13. helmikuuta 2009
Ensimmäinen Lähetetty (Arvio)
Maanantai 16. helmikuuta 2009
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 7. marraskuuta 2018
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 9. lokakuuta 2018
Viimeksi vahvistettu
Maanantai 1. lokakuuta 2018
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Aivojen sairaudet
- Keskushermoston sairaudet
- Hermoston sairaudet
- Neurologiset ilmenemismuodot
- Basal ganglia -taudit
- Liikkumishäiriöt
- Synukleinopatiat
- Neurodegeneratiiviset sairaudet
- Parkinsonin tauti
- Dyskinesiat
- Parkinsonin häiriöt
- Huumeiden fysiologiset vaikutukset
- Neurotransmitterit
- Farmakologisen vaikutuksen molekyylimekanismit
- Entsyymin estäjät
- Dopamiini-aineet
- Parkinsonin vastaiset aineet
- Dyskinesian vastaiset aineet
- Aromaattiset aminohappodekarboksylaasi-inhibiittorit
- Levodopa
- Carbidopa
Muut tutkimustunnusnumerot
- P05550
- MK-3814-023 (Muu tunniste: Merck Study Number)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
JOO
IPD-suunnitelman kuvaus
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset SCH 420814 10 mg
-
Merck Sharp & Dohme LLCValmis
-
Merck Sharp & Dohme LLCValmisParkinsonin tauti | Idiopaattinen Parkinsonin tauti | Idiopaattinen Parkinsonin tauti
-
Merck Sharp & Dohme LLCValmis
-
Merck Sharp & Dohme LLCValmis
-
Merck Sharp & Dohme LLCLopetettu
-
Merck Sharp & Dohme LLCLopetettuParkinsonin häiriöt | Dyskinesia, huumeiden aiheuttama | Akathisia, huumeiden aiheuttama
-
Merck Sharp & Dohme LLCValmisPrimaarinen hyperkolesterolemia | Sekahyperlipidemia
-
Humanis Saglık Anonim SirketiValmis
-
Merck Sharp & Dohme LLCLopetettuParkinsonin tauti | Idiopaattinen Parkinsonin tauti